InvestorsHub Logo
Followers 3
Posts 104
Boards Moderated 0
Alias Born 07/15/2016

Re: Samsa post# 121

Friday, 11/04/2016 12:06:17 PM

Friday, November 04, 2016 12:06:17 PM

Post# of 138
No reason for SUPN to sell off. FDA approval for migraine indication is only four months away. This should add significant sales. Also, existing prescription sales continue to grow. Plus all active FDA trials continue to look good. Can't find any negatives to SUPN's fundamentals. Puzzling dip in price.
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SUPN News